semaglutide nash and MASH resolution: A pooled analysis of recent trials - Abouelmagd - 2025 - Diabetes, Obesity and Metabolism Modulation of metabolic, inflammatory and

Dizziness is a recognised adverse reaction listed in the Summary of Product Characteristics for several GLP-1 medications

In addition, the trials included in the meta-analysis were not designed to assess cancer outcomes

Follow the instructions from your prescriber carefully and stay in touch to help make the transition smooth and successful

Clinical Topics: Arrhythmias and Clinical EP, COVID-19 Hub, Heart Failure and Cardiomyopathies, Noninvasive Imaging, Atrial Fibrillation/Supraventricular Arrhythmias, Acute Heart Failure, Echocardiography/Ultrasound Keywords: ESC Congress, ESC24, Diabetes Mellitus, Type 2, Atrial Fibrillation, Heart Failure, COVID-19, Obesity, Echocardiography